ReviewInternational journal of clinical and experimental medicine2015
The role of MTDH/AEG-1 in the progression of cancer.
Review in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Computational Elucidation of Hub Genes and Pathways Correlated with the Development of 5-Fluorouracil Resistance in HCT 116 Colorectal Carcinoma Cell Line.Biochemical genetics · 2026Article
- Proteomics discovery of MTDH and SND1 interaction vulnerabilities in ovarian cancer.Scientific reports · 2025Article
- Hippocampus- and neocortex-specific deletion of Aeg-1 causes learning memory impairment and depression in mice.Cell death & disease · 2025Article
- SNHG1: Redefining the Landscape of Hepatocellular Carcinoma through Long Noncoding RNAs.Biomedicines · 2024Review
- Metadherin-driven promotion of cancer stem cell phenotypes and its effect on immunity in hepatocellular carcinoma.World journal of gastroenterology · 2024Article
- USP7 promotes cervical cancer progression by stabilizing MTDH expression through deubiquitination.Journal of cancer research and clinical oncology · 2024Article
- The Role of Long Noncoding RNAs (lncRNAs) in Esophageal Cancer Therapy Resistance and Metastasis.Biomedicines · 2024Review
- AEG-1 as a Novel Therapeutic Target in Colon Cancer: A Study from Silencing AEG-1 in BALB/c Mice to Large Data Analysis.Current gene therapy · 2024Article
- Distinct molecular targets of ProEGCG from EGCG and superior inhibition of angiogenesis signaling pathways for treatment of endometriosis.Journal of pharmaceutical analysis · 2024Article
- SND1 binds to ERG and promotes tumor growth in genetic mouse models of prostate cancer.Nature communications · 2023Article
- miRNA-559 and MTDH as possible diagnostic markers of psoriasis: Role of PTEN/AKT/FOXO pathway in disease pathogenesis.Molecular and cellular biochemistry · 2023Article
- Metadherin Regulates Inflammatory Breast Cancer Invasion and Metastasis.International journal of molecular sciences · 2023Article
- Harnessing the immune system against cancer: current immunotherapy approaches and therapeutic targets.Molecular biology reports · 2021Review
- AEG-1 silencing attenuates M2-polarization of glioma-associated microglia/macrophages and sensitizes glioma cells to temozolomide.Scientific reports · 2021Article
- Emerging Role and Clinicopathological Significance of AEG-1 in Different Cancer Types: A Concise Review.Cells · 2021Review
- miRNAs Involved in Esophageal Carcinogenesis and miRNA-Related Therapeutic Perspectives in Esophageal Carcinoma.International journal of molecular sciences · 2021Review
- AEG-1 Regulates TWIK-1 Expression as an RNA-Binding Protein in Astrocytes.Brain sciences · 2021Article
- Overexpression of microRNA-124-5p sensitizes non-small cell lung cancer cells to treatment with 5-fluorouracil via AEG-1 regulation.Oncology letters · 2021Article
- MiR-128 suppresses metastatic capacity by targeting metadherin in breast cancer cells.Biological research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer progression is driven by an accumulation of numerous genetic and epigenetic alterations in cancer cells themselves as well as constructional changes in their microenvironment. Metadherin (MTDH)/Astrocyte elevated gene-1 (AEG-1) has emerged in recent years as a key contributor to the carcinogenic process in diverse organs and tissues. As a multifunctional mediator of carcinogenesis, MTDH/AEG-1 has been found to be involved in multiple signaling pathways, such as: PI3K/Akt, NF-κB, Wnt/β-catenin and MAPK. Overexpression of MTDH/AEG-1 is observed in a variety of cancers belonging to all biological systems, and has crucial relevance with cancer progression, including initiation, proliferation, invasion, metastasis and chemoresistance. In addition, a plethora of studies have convincingly demonstrated that MTDH/AEG-1 overexpression markedly correlates with poor clinical prognosis. These findings suggest that MTDH/AEG-1 may be used as a potential biomarker for the diagnosis of cancer, monitoring of cancer progression, and target therapies which may simultaneously inhibit tumor growth, block metastasis, and intensify the efficacy of chemotherapeutic treatments.
Indexed as
Identifiers
26131054PMC4484038What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.